Advances in minimal residual disease monitoring in multiple myeloma

References

• van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–427.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood. 2011;117(18):4701–4705.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Laubach JP, Kaufman JL, Sborov DW, et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of griffin after 24 months of maintenance. Blood. 2021;138(Suppl 1):79–79.
   Google Scholar
• Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(10):1378–1390.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284.
   PubMed Web of Science ®Google Scholar
• Ding H, Xu J, Lin Z, et al. Minimal residual disease in multiple myeloma: current status. Biomark Res. 2021;9(1):75.
   PubMed Web of Science ®Google Scholar
• Diamond BT, Rustad E, Maclachlan K, et al. Defining the undetectable: the current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. Blood Rev. 2021;46:100732.
   PubMed Web of Science ®Google Scholar
• Cho H, Shin S, Chung H, et al. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma. Br J Haematol. 2022;198(3):503–514.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28–35.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4(14):3295–3301.
   PubMed Web of Science ®Google Scholar
• Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–2464.
   PubMed Web of Science ®Google Scholar
• Mills JR, Barnidge DR, Dispenzieri A, et al. High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer J. 2017;7(8):e590.
   PubMedGoogle Scholar
• Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–5999.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(25):2901–2912.
   PubMed Web of Science ®Google Scholar
• Puig N, Contreras Sanfeliciano T, Paiva B, et al. Assessment of treatment response by IFE, next generation flow cytometry and mass spectrometry coupled with liquid chromatography in the GEM2012MENOS65 clinical trial. Blood. 2021;138(Suppl 1):544–544.
   PubMedGoogle Scholar
• Derman BA, Stefka AT, Jiang K, et al. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021;11(2):19.
   PubMed Web of Science ®Google Scholar
• Langerhorst P, Noori S, Zajec M, et al. Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow. Clin Chem. 2021;67(12):1689–1698.
   PubMed Web of Science ®Google Scholar
• Jacobs JFM, Turner KA, Graziani MS, et al. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med. 2020;58(4):547–559.
   PubMed Web of Science ®Google Scholar
• Turner KA, Frinack JL, Ettore MW, et al. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis. Clin Chem Lab Med. 2020;58(4):533–546.
   PubMed Web of Science ®Google Scholar
• Willrich MA, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med. 2016;54(6):907–919.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R, Merlini G, et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–224.
   PubMed Web of Science ®Google Scholar
• Udd KA, Spektor TM, Berenson JR. Monitoring multiple myeloma. Clin Adv Hematol Oncol. 2017;15(12):951–961.
   PubMedGoogle Scholar
• David FK, Lee S. Challenges of measuring monoclonal proteins in serum. Clin Chem Lab Med. 2016;54(6):947–961.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau J-L, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood. 2011;117(18):4691–4695.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nishiwaki K, Yano S. Treatment strategy for multiple myeloma to improve immunological environment and maintain MRD negativity. Cancers. 2021;13(19):4867–4891.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anaissie E, Haessler J, et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer. 2008;113(2):355–359.
   PubMed Web of Science ®Google Scholar
• Lancman G, Sastow DL, Cho HJ, et al. Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov. 2021;2(5):423–433.
   PubMedGoogle Scholar
• Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059–3068.
   PubMed Web of Science ®Google Scholar
• Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–2103.
   PubMed Web of Science ®Google Scholar
• Takamatsu H. Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan. Int J Hematol. 2020;111(4):519–529.
   PubMed Web of Science ®Google Scholar
• Bertamini L, Oliva S, Rota-Scalabrini D, et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(27):3120–3131.
   PubMed Web of Science ®Google Scholar
• Garces JJ, Cedena MT, Puig N, et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol. 2022;40(27):3151–3161.
   PubMed Web of Science ®Google Scholar
• Shanmugam V, Parnes A, Kalyanaraman R, et al. Clinical utility of targeted next-generation sequencing–based screening of peripheral blood in the evaluation of cytopenias. Blood. 2019;134(24):2222–2225.
   PubMed Web of Science ®Google Scholar
• Notarfranchi L, Zherniakova A, Lasa M, et al. Ultra-sensitive assessment of measurable residual disease (MRD) in peripheral blood (PB) of multiple myeloma (MM) patients using bloodflow. Blood. 2022;140(Suppl 1):2095–2097.
   Google Scholar
• Bertamini L, D'Agostino M, Gay F. MRD assessment in multiple myeloma: progress and challenges. Curr Hematol Malig Rep. 2021;16(2):162–171.
   PubMed Web of Science ®Google Scholar
• Hillengass J, Landgren O. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”. Leuk Lymphoma. 2013;54(7):1355–1363.
   PubMed Web of Science ®Google Scholar
• Zamagni E, Tacchetti P, Barbato S, et al. Role of imaging in the evaluation of minimal residual disease in multiple myeloma patients. JCM. 2020;9(11):3519–3528.
   Google Scholar
• Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302–e312.
   PubMed Web of Science ®Google Scholar
• Cavo M, Terpos E, Nanni C, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group. Lancet Oncol. 2017;18(4):e206–e217.
   PubMed Web of Science ®Google Scholar
• Jamet B, Zamagni E, Nanni C, et al. Functional imaging for therapeutic assessment and minimal residual disease detection in multiple myeloma. IJMS. 2020;21(15):5406.
   Google Scholar
• Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [(18)fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35(25):2911–2918.
   PubMed Web of Science ®Google Scholar
• Rasche L, Angtuaco E, McDonald JE, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130(1):30–34.
   PubMed Web of Science ®Google Scholar
• Daniele P, Mamolo C, Cappelleri JC, et al. Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. PLOS One. 2022;17(5):e0267979.
   PubMed Web of Science ®Google Scholar
• Delgado JA, Guillen-Grima F, Moreno C, et al. A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates. J Immunol Methods. 2017;442:54–58.
   PubMed Web of Science ®Google Scholar
• Foureau DM, Paul BA, Guo F, et al. Standardizing clinical workflow for assessing minimal residual disease by flow cytometry in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(1):e41–e50.
   PubMed Web of Science ®Google Scholar
• Cloos J, Harris JR, Janssen J, et al. Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia. J Vis Exp. 2018;133:e56386.
   Google Scholar
• Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431–438.
   PubMed Web of Science ®Google Scholar
• Murray DL, Dasari S. Clinical mass spectrometry approaches to myeloma and amyloidosis. Clin Lab Med. 2021;41(2):203–219.
   PubMed Web of Science ®Google Scholar
• Murray DL. Bringing mass spectrometry into the care of patients with multiple myeloma. Int J Hematol. 2022;115(6):790–798.
   PubMed Web of Science ®Google Scholar
• Barnidge DR, Dasari S, Botz CM, et al. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J Proteome Res. 2014;13(3):1419–1427.
   PubMed Web of Science ®Google Scholar
• Barnidge DR, Tschumper RC, Theis JD, et al. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS. J Proteome Res. 2014;13(4):1905–1910.
   PubMed Web of Science ®Google Scholar
• Mills JR, Barnidge DR, Murray DL. Detecting monoclonal immunoglobulins in human serum using mass spectrometry. Methods. 2015;81:56–65.
   PubMed Web of Science ®Google Scholar
• Campbell L, Simpson D, Ramasamy K, et al. Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins. Clin Biochem. 2021;95:81–83.
   PubMed Web of Science ®Google Scholar
• Mills JR, Kohlhagen MC, Dasari S, et al. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62(10):1334–1344.
   PubMed Web of Science ®Google Scholar
• Puig N, Contreras MT, Agullo C, et al. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv. 2022;6(11):3234–3239.
   PubMed Web of Science ®Google Scholar
• Singhal N, Kumar M, Kanaujia PK, et al. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol. 2015;6:1–16.
   PubMed Web of Science ®Google Scholar
• Mellors PW, Dasari S, Kohlhagen MC, et al. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer J. 2021;11(3):50–58.
   PubMed Web of Science ®Google Scholar
• Dasari S, Kohlhagen MC, Dispenzieri A, et al. Detection of plasma cell disorders by mass spectrometry: a comprehensive review of 19,523 cases. Mayo Clin Proc. 2022;97(2):294–307.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Westhrin M, Bondt A, et al. Serum protein N-glycosylation changes in multiple myeloma. Biochim Biophys Acta Gen Subj. 2019;1863(5):960–970.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Larson DR, Rajkumar SV, et al. N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. Leukemia. 2020;34(10):2749–2753.
   PubMed Web of Science ®Google Scholar
• Sidana S, Murray DL, Dasari S, et al. Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. Am j of Hematol. 2020;95(9):e222–e225.
   PubMed Web of Science ®Google Scholar
• Juskewitch JE, Murray JD, Norgan AP, et al. In from the cold: M-protein light chain glycosylation is positively associated with cold agglutinin titer levels. Transfusion. 2021;61(4):1302–1311.
   PubMed Web of Science ®Google Scholar
• Sepiashvili L, Kohlhagen MC, Snyder MR, et al. Direct detection of monoclonal free light chains in serum by use of immunoenrichment-coupled MALDI-TOF mass spectrometry. Clin Chem. 2019;65(8):1015–1022.
   PubMed Web of Science ®Google Scholar
• Giles HV, Wechalekar A, Pratt G. The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: where are we now and which questions remain unanswered? Br J Haematol. 2022;198(4):641–653.
   PubMed Web of Science ®Google Scholar
• Langerhorst P, Brinkman AB, VanDuijn MM, et al. Clonotypic features of rearranged immunoglobulin genes yield personalized biomarkers for minimal residual disease monitoring in multiple myeloma. Clin Chem. 2021;67(6):867–875.
   PubMed Web of Science ®Google Scholar
• Noori S, Zajec M, Russcher H, et al. Retrospective longitudinal monitoring of multiple myeloma patients by mass spectrometry using archived serum protein electrophoresis gels and de novo sequence analysis. Hemasphere. 2022;6(8):e758–e762.
   PubMed Web of Science ®Google Scholar
• Bergen HRIII, Dasari S, Dispenzieri A, et al. Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration. Clin Chem. 2016;62(1):243–251.
   PubMed Web of Science ®Google Scholar
• Dupre M, Duchateau M, Sternke-Hoffmann R, et al. De novo sequencing of antibody light chain proteoforms from patients with multiple myeloma. Anal Chem. 2021;93(30):10627–10634.
   PubMed Web of Science ®Google Scholar
• Liyasova M, McDonald Z, Taylor P, et al. A personalized mass spectrometry-based assay to monitor M-protein in patients with multiple myeloma (EasyM). Clin Cancer Res. 2021;27(18):5028–5037.
   PubMed Web of Science ®Google Scholar
• McDonald Z, Taylor P, Liyasova M, et al. Mass spectrometry provides a highly sensitive noninvasive means of sequencing and tracking M-protein in the blood of multiple myeloma patients. J Proteome Res. 2021;20(8):4176–4185.
   PubMed Web of Science ®Google Scholar
• Zajec M, Jacobs JFM, Groenen P, et al. Development of a targeted mass spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies. J Proteome Res. 2018;17(3):1326–1333.
   PubMed Web of Science ®Google Scholar
• Martins CO, Huet S, Yi SS, et al. Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma. J Mol Diagn. 2020;22(7):901–911.
   PubMed Web of Science ®Google Scholar
• Dau T, Bartolomucci G, Rappsilber J. Proteomics using protease alternatives to trypsin benefits from sequential digestion with trypsin. Anal Chem. 2020;92(14):9523–9527.
   PubMed Web of Science ®Google Scholar
• Borras E, Sabido E. What is targeted proteomics? A concise revision of targeted acquisition and targeted data analysis in mass spectrometry. Proteomics. 2017;17(17–18):1700180.
   Web of Science ®Google Scholar
• Stefani NT. Mass spectrometry. In: Clarke W, Marzinke M, editors. Contemporary practice in clinical chemistry. 4th ed. Washington (DC): Academic press; 2019. p. 171–185.
   Google Scholar
• Beck O, Rylski A, Stephanson NN. Application of liquid chromatography combined with high resolution mass spectrometry for urine drug testing. In: Dasgupta A, editor. Critical issues in alcohol and drugs of abuse testing. 2nd ed. Cambridge (MA): Academic press; 2019. p. 321–332.
   Google Scholar
• Krasny L, Huang PH. Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. Mol Omics. 2021;17(1):29–42.
   PubMed Web of Science ®Google Scholar
• Remily-Wood ER, Benson K, Baz RC, et al. Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients. Proteomics Clin Appl. 2014;8(9–10):783–795.
   PubMed Web of Science ®Google Scholar
• Li J, Smith LS, Zhu HJ. Data-independent acquisition (DIA): an emerging proteomics technology for analysis of drug-metabolizing enzymes and transporters. Drug Discov Today Technol. 2021;39:49–56.
   PubMedGoogle Scholar
• He L, Anderson LC, Barnidge DR, et al. Classification of plasma cell disorders by 21 tesla fourier transform ion cyclotron resonance top-down and middle-down MS/MS analysis of monoclonal immunoglobulin light chains in human serum. Anal Chem. 2019;91(5):3263–3269.
   PubMed Web of Science ®Google Scholar
• Santockyte R, Puig O, Zheng N, et al. High-throughput therapeutic antibody interference-free high-resolution mass spectrometry assay for monitoring M-proteins in multiple myeloma. Anal Chem. 2021;93(2):834–842.
   PubMed Web of Science ®Google Scholar
• Zajec M, Jacobs JFM, de Kat Angelino CM, et al. Integrating serum protein electrophoresis with mass spectrometry, a new workflow for M-protein detection and quantification. J Proteome Res. 2020;19(7):2845–2853.
   PubMed Web of Science ®Google Scholar
• Kohlhagen M, Dasari S, Willrich M, et al. Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab. Clin Chem Lab Med. 2020;59(1):155–163.
   PubMed Web of Science ®Google Scholar
• Seger C, Salzmann L. After another decade: LC-MS/MS became routine in clinical diagnostics. Clin Biochem. 2020;82:2–11.
   PubMed Web of Science ®Google Scholar
• Schokker S, Fusetti F, Bonardi F, et al. Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab. MAbs. 2020;12(1):e17954921–e17954927.
   Web of Science ®Google Scholar
• Santockyte R, Jin C, Pratt J, et al. Sensitive multiple myeloma disease monitoring by mass spectrometry. Blood Cancer J. 2021;11(4):78.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Guidance for industry: hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. Silver Spring, MD; 2020. Standard No. FDA-2018-D-3090.
   Google Scholar
• Miller WG, Greenberg N. Harmonization and standardization: where are we now? J Appl Lab Med. 2021;6(2):510–521.
   PubMedGoogle Scholar
• Ceriotti F, Cobbaert C. Harmonization of external quality assessment schemes and their role clinical chemistry and beyond. Clin Chem Lab Med. 2018;56(10):1587–1590.
   PubMed Web of Science ®Google Scholar
• ISO. In vitro diagnostic medical devices—Requirements for international harmonisation protocols establishing metrological traceability of values assigned to calibrators and human samples. ISO 21151:2020. Geneva, Switzerland: International Organization for Standardization; 2020. Available from: https://www.iso.org/standard/69985.html
   Google Scholar
• Kendrick F, Evans ND, Arnulf B, et al. Analysis of a compartmental model of endogenous immunoglobulin G metabolism with application to multiple myeloma. Front Physiol. 2017;8:1–18.
   PubMed Web of Science ®Google Scholar
• van Tetering G, Evers M, Chan C, et al. Fc engineering strategies to advance IgA antibodies as therapeutic agents. Antibodies. 2020;9(4):70.
   Web of Science ®Google Scholar
• Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684–1690.
   PubMed Web of Science ®Google Scholar
• Jacobs JFM, Mould DR. The role of FcRn in the pharmacokinetics of biologics in patients with multiple myeloma. Clin Pharmacol Ther. 2017;102(6):903–904.
   PubMed Web of Science ®Google Scholar
• Noori S, Wijnands C, Langerhorst P, et al. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J. 2023;13(1):1–3.
   PubMed Web of Science ®Google Scholar
• Liu L, Wertz WJ, Kondisko A, et al. Incidence and management of therapeutic monoclonal antibody interference in monoclonal gammopathy monitoring. J Appl Lab Med. 2020;5(1):29–40.
   PubMedGoogle Scholar
• Noori S, Verkleij CPM, Zajec M, et al. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. Clin Chem Lab Med. 2021;59(12):1963–1971.
   PubMed Web of Science ®Google Scholar
• Blade J, Beksac M, Caers J, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12(3):1–10.
   PubMed Web of Science ®Google Scholar
• Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068–2076.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Mitchell A, Waheed S, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819–1823.
   PubMed Web of Science ®Google Scholar
• Chen CI, Masih-Khan E, Jiang H, et al. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol. 2013;162(4):483–488.
   PubMed Web of Science ®Google Scholar
• Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016;91(6):575–580.
   PubMed Web of Science ®Google Scholar
• Zajec M, Frerichs KA, van Duijn MM, et al. Cerebrospinal fluid penetrance of daratumumab in leptomeningeal multiple myeloma. Hemasphere. 2020;4(4):e413.
   PubMed Web of Science ®Google Scholar